Bullhound Capital led the Series C financing, which stands as Europe's largest private quantum funding round.
"Globally, it represents a clear shift in the market from long-term promise to near-term delivery in quantum computing. For OQC, this gives us the capital to scale internationally, advance our technology roadmap, and meet increasing demand from customers seeking secure, scalable access to quantum computing infrastructure."
Albion VC led the Series A round to support nationwide clinic expansion and international growth.
"The healthcare supply-demand gap remains a major challenge, with over 390,000 people waiting for treatable MSK care in England alone. Finn, Ric and the team have proven that autonomous care pathways can deliver strong outcomes at scale. They’ve earned NHS trust, navigated complex regulations, and built a service that improves access to care. Having proven the model in MSK, we believe the opportunity ahead is far larger,"
The oversubscribed round was co-led by IQ Capital and Molten Ventures to expand the company's immune profiling platform.
"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth."
Vinted Ventures leads the latest round alongside TQ Ventures, Balderton Capital, Earlybird, and Seedcamp to scale operations.
"The next generation won’t browse static listings the way their parents did—they’ll discover and buy through video, conversation, and live interaction, across every category"